Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: A case for more innovation

JAMA

Volumn 292, Issue 17, 2004, Pages 2150-2151

  Chen, Eric X ^a   Tannock, Ian F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER RISK; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MAXIMUM TOLERATED DOSE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SIDE EFFECT; TOXICITY; NEOPLASM; NOTE; PHASE 1 CLINICAL TRIAL; RISK; STANDARD; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; HUMANS; NEOPLASMS; RISK; TREATMENT OUTCOME;

EID: 7244231121     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.17.2150     Document Type: Editorial

References (11)

1. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol. 2000;18:684-692.
2. Meropol NJ, Weinfurt KP, Burnett CB, et al. Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol. 2003;21:2589-2596.
3. Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical trials. Ann Oncol. 1990;1:175-181.
4. Von Hoff DD, Turner J. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs. 1991;9:115-122.
5. Itoh K, Sasaki Y, Miyata Y, et al. Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan. Cancer Chemother Phamacol. 1994;34:451-454.
6. Agrawal M, Emanuel EJ. Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA. 2003;290:1075-1082.
7. Roberts TG, Goulart BH, Squitieri L, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA. 2004;292:2130-2140.
8. Krzyzanowska MK, Pintilie M, Tannock IF. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA. 2003;290:495-501.
9. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997;89:1138-1147.
10. Dent SF, Eisenhauer EA. Phase I trial design: are new methodologies being put into practice? Ann Oncol. 1996;7:561-566.
11. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst. 2004;96:990-997.